The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.
 
Atsushi Natsume
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; SRL Diagnostics; Teijin Pharma
Consulting or Advisory Role - NGK Spark Plug, Inc
Research Funding - Chugai Pharma; Daiichi Sankyo; Takeda
 
Toshihiko Wakabayashi
No Relationships to Disclose
 
Yasuji Miyakita
No Relationships to Disclose
 
Yoshitaka Narita
Honoraria - Abbvie; Chugai Pharma; Daiichi Sankyo; Eisai; MSD; Otsuka
Research Funding - Abbvie; Chugai Pharma; Eisai; EPS Associates Co., Ltd.; MSD; Ono Pharmaceutical; SBI Pharmaceuticals; Toshiba
 
Yohei Mineharu
No Relationships to Disclose
 
Yoshiki Arakawa
Speakers' Bureau - Abbvie; Brainlab; Chugai Pharma; CSL Behring; Daiichi Sankyo; Eisai; Meiji Seika Kaisha; Merck; Nippon Kayaku; Novocure; Otsuka; UCB
Research Funding - Brainlab; Chugai Pharma; CSL Behring; Daiichi Sankyo; Eisai; Meiji Seika Kaisha; Merck; Mitsubishi Tanabe Pharma; Nihon Medi-Physics; Pfizer; Philips Electronics; Sanofi; Siemens; Takeda; Zeiss
 
Fumiyuki Yamasaki
No Relationships to Disclose
 
Kazuhiko Sugiyama
Honoraria - Meiji Seika Kaisha; Nobelpharma
Consulting or Advisory Role - Daiichi Sankyo
 
Nobuhiro Hata
No Relationships to Disclose
 
Yoshihiro Muragaki
Consulting or Advisory Role - Abbvie
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Eisai; Hitachi Chemical; MSD; Novartis; Otsuka
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Hitachi Chemical (Inst); MSD (Inst); Otsuka (Inst)
 
Ryo Nishikawa
Honoraria - Abbvie; Chugai Pharma; Eisai; MSD
Consulting or Advisory Role - Daiichi Sankyo; Novocure; Ono Pharmaceutical
Research Funding - Chugai Pharma (Inst); Eisai (Inst); MSD (Inst)
Expert Testimony - Daiichi Sankyo; Novocure; Ono Pharmaceutical
 
Naoki Shinojima
No Relationships to Disclose
 
Toshihiro Kumabe
Honoraria - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Kowa; MSD; Senju Pharmaceutical; Takeda; Teijin Pharma; Tsumura & Co.; UCB
 
Ryuta Saito
No Relationships to Disclose
 
Kazumi Ito
Employment - Daiichi Sankyo
 
Masaya Tachibana
Employment - Daiichi Sankyo
 
Yasuyuki Kakurai
Employment - Daiichi Sankyo
 
Soichiro Nishijima
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Hiroshi Tsubouchi
Employment - Daiichi Sankyo